RPTX Repare Therapeutics | $1.32
| 12/13/2024 | Reiterated by | Lifesci Capital | Analyst C. Zhu | Outperform -> Market Perform | | N/A | View details for Lifesci Capital rating of Repare Therapeutics (NASDAQ:RPTX) on 12/13/2024 |
KURA Kura Oncology | $9.01
+0.4% | 10/22/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | High | View details for Lifesci Capital rating of Kura Oncology (NASDAQ:KURA) on 10/22/2024 |
OKUR OnKure Therapeutics | $8.38
+4.1% | 10/10/2024 | Upgraded by | Lifesci Capital | Analyst S. Slutsky | Strong-Buy | | High | View details for Lifesci Capital rating of OnKure Therapeutics (NASDAQ:OKUR) on 10/10/2024 |
LQDA Liquidia | $11.10
+4.8% | 10/2/2024 | Upgraded by | Lifesci Capital | Analyst C. Jubinville | Strong-Buy | | High | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/2/2024 |
LQDA Liquidia | $11.10
+4.8% | 10/3/2024 | Initiated by | Lifesci Capital | - | Outperform | $30.00 | Low | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/3/2024 |
ORKA Oruka Therapeutics | $20.31
-2.2% | 9/16/2024 | Initiated by | Lifesci Capital | Analyst S. Slutsky | Outperform | $41.00 | Medium | View details for Lifesci Capital rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/16/2024 |
|
AURA Aura Biosciences | $8.20
+1.1% | 9/9/2024 | Upgraded by | Lifesci Capital | Analyst A. Dhankher | Strong-Buy | | Medium | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 9/9/2024 |
CELC Celcuity | $12.46
+3.8% | 8/26/2024 | Initiated by | Lifesci Capital | Analyst O. Mccammon | Outperform | $27.00 | Low | View details for Lifesci Capital rating of Celcuity (NASDAQ:CELC) on 8/26/2024 |
CRBP Corbus Pharmaceuticals | $13.00
-2.5% | 8/21/2024 | Upgraded by | Lifesci Capital | Analyst M. Belghiti | Strong-Buy | | Low | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 8/21/2024 |
ALXO ALX Oncology | $1.62
+9.5% | 7/31/2024 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Strong-Buy -> Hold | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 7/31/2024 |
RPTX Repare Therapeutics | $1.32
| 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Repare Therapeutics (NASDAQ:RPTX) on 7/29/2024 |
NUVL Nuvalent | $84.22
-0.5% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 7/29/2024 |
MRUS Merus | $41.85
-0.6% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Merus (NASDAQ:MRUS) on 7/29/2024 |
MRSN Mersana Therapeutics | $1.60
-8.0% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Mersana Therapeutics (NASDAQ:MRSN) on 7/29/2024 |
IDYA IDEAYA Biosciences | $25.61
+3.3% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of IDEAYA Biosciences (NASDAQ:IDYA) on 7/29/2024 |
DNTH Dianthus Therapeutics | $23.80
+3.3% | 6/11/2024 | Upgraded by | Lifesci Capital | Analyst R. Katkhuda | Strong-Buy | | Low | View details for Lifesci Capital rating of Dianthus Therapeutics (NASDAQ:DNTH) on 6/11/2024 |
CALT Calliditas Therapeutics AB (publ) | $40.00
| 5/28/2024 | Downgraded by | Lifesci Capital | Analyst R. Katkhuda | Strong-Buy -> Hold | | Low | View details for Lifesci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 5/28/2024 |
CATX Perspective Therapeutics | $2.85
+0.4% | 5/6/2024 | Reiterated by | Lifesci Capital | Analyst A. Dhankher | Outperform | | N/A | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 5/6/2024 |
MLYS Mineralys Therapeutics | $12.34
+4.3% | 3/26/2024 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024 |
GPCR Structure Therapeutics | $27.90
-6.9% | 2/27/2024 | Reiterated by | Lifesci Capital | Analyst M. Belghiti | Outperform | | Low | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024 |
VTYX Ventyx Biosciences | $2.24
-1.8% | 2/28/2024 | Upgraded by | Lifesci Capital | Analyst S. Slutsky | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 2/28/2024 |
LRMR Larimar Therapeutics | $4.01
+0.8% | 2/20/2024 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024 |
INBX Inhibrx | $14.60
+5.2% | 1/23/2024 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 1/23/2024 |
IVA Inventiva | $2.35
-0.8% | 1/5/2024 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024 |
TARS Tarsus Pharmaceuticals | $52.91
+1.8% | 12/26/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023 |
RCKT Rocket Pharmaceuticals | $11.56
+1.9% | 12/26/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023 |
SYRE Spyre Therapeutics | $23.86
+3.2% | 12/4/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Spyre Therapeutics (NASDAQ:SYRE) on 12/4/2023 |
TCRX TScan Therapeutics | $2.97
+1.4% | 11/27/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of TScan Therapeutics (NASDAQ:TCRX) on 11/27/2023 |
VTYX Ventyx Biosciences | $2.24
-1.8% | 11/7/2023 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/7/2023 |
VERV Verve Therapeutics | $5.74
+11.2% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 8/8/2023 |
INBX Inhibrx | $14.60
+5.2% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 8/8/2023 |
TNYA Tenaya Therapeutics | $1.67
+18.4% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/8/2023 |
PYXS Pyxis Oncology | $1.69
+9.7% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 4/26/2023 |
OLMA Olema Pharmaceuticals | $6.10
+5.4% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 4/26/2023 |
INBX Inhibrx | $14.60
+5.2% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 4/26/2023 |
AVDL Avadel Pharmaceuticals | $10.31
+2.0% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 4/26/2023 |
ALXO ALX Oncology | $1.62
+9.5% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 4/26/2023 |
IRON Disc Medicine | $64.50
+2.5% | 4/24/2023 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Disc Medicine (NASDAQ:IRON) on 4/24/2023 |
AKRO Akero Therapeutics | $29.34
+3.3% | 4/11/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Akero Therapeutics (NASDAQ:AKRO) on 4/11/2023 |
IFRX InflaRx | $2.24
+5.2% | 4/5/2023 | Upgraded by | Lifesci Capital | - | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 4/5/2023 |
Why I'm telling friends to avoid gold stocks (Ad) Back in November, gold made a tiny move of 1.6%.
But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week.
It happened again in March. Gold nudged up 1.2%.
This time? A 104% overnight gain.
And in June? A 1% gold move turned into a 74% gain in two weeks.
Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now.
There's a more lucrative way to play the gold market as we enter a new breakout period.
It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. |
CRNX Crinetics Pharmaceuticals | $53.60
+1.6% | 3/27/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 3/27/2023 |
OBIO Orchestra BioMed | $4.92
+2.5% | 3/8/2023 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | Low | View details for Lifesci Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/8/2023 |
ELVN Enliven Therapeutics | $22.47
-1.7% | 3/7/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Enliven Therapeutics (NASDAQ:ELVN) on 3/7/2023 |
MLTX MoonLake Immunotherapeutics | $52.17
+0.6% | 12/21/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | N/A | View details for Lifesci Capital rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 12/21/2022 |
PYXS Pyxis Oncology | $1.69
+9.7% | 12/1/2022 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 12/1/2022 |
ATXS Astria Therapeutics | $9.56
+1.2% | 11/28/2022 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Astria Therapeutics (NASDAQ:ATXS) on 11/28/2022 |
ALXO ALX Oncology | $1.62
+9.5% | 11/8/2022 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/8/2022 |
VYNE VYNE Therapeutics | $2.50
+4.6% | 8/12/2022 | Downgraded by | Lifesci Capital | Analyst P. Dolezal | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 8/12/2022 |
LRMR Larimar Therapeutics | $4.01
+0.8% | 8/12/2022 | Upgraded by | Lifesci Capital | Analyst P. Dolezal | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/12/2022 |
TNYA Tenaya Therapeutics | $1.67
+18.4% | 6/16/2022 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 6/16/2022 |
VERA Vera Therapeutics | $42.60
+1.3% | 3/28/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Vera Therapeutics (NASDAQ:VERA) on 3/28/2022 |
ELDN Eledon Pharmaceuticals | $4.36
+3.3% | 3/25/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Medium | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/25/2022 |
LRMR Larimar Therapeutics | $4.01
+0.8% | 2/16/2022 | Downgraded by | Lifesci Capital | Analyst Patrick Dolezal | Outperform -> Market Perform | $3.00 | Medium | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/16/2022 |
VERV Verve Therapeutics | $5.74
+11.2% | 12/22/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 12/22/2021 |
ALLK Allakos | $1.20
-7.0% | 12/22/2021 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | High | View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 12/22/2021 |
NNOX Nano-X Imaging | $6.76
+2.9% | 11/17/2021 | Downgraded by | Lifesci Capital | Analyst R. Rakhit | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 11/17/2021 |
VTYX Ventyx Biosciences | $2.24
-1.8% | 11/15/2021 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/15/2021 |
ALXO ALX Oncology | $1.62
+9.5% | 11/4/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/4/2021 |
PYXS Pyxis Oncology | $1.69
+9.7% | 11/2/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 11/2/2021 |
RCKT Rocket Pharmaceuticals | $11.56
+1.9% | 10/24/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/24/2021 |
DRIO DarioHealth | $0.80
+8.1% | 8/26/2021 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | High | View details for Lifesci Capital rating of DarioHealth (NASDAQ:DRIO) on 8/26/2021 |
VRDN Viridian Therapeutics | $19.03
+1.6% | 8/24/2021 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Viridian Therapeutics (NASDAQ:VRDN) on 8/24/2021 |
LRMR Larimar Therapeutics | $4.01
+0.8% | 8/4/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/4/2021 |
OLMA Olema Pharmaceuticals | $6.10
+5.4% | 6/21/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | High | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 6/21/2021 |
NNOX Nano-X Imaging | $6.76
+2.9% | 6/3/2021 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | High | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 6/3/2021 |
VECT VectivBio | $16.85
| 5/4/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of VectivBio (NASDAQ:VECT) on 5/4/2021 |
ADVM Adverum Biotechnologies | $4.74
+0.9% | 4/29/2021 | Downgraded by | Lifesci Capital | Analyst P. Dolezal | Outperform -> Market Perform | | High | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/29/2021 |
ELDN Eledon Pharmaceuticals | $4.36
+3.3% | 3/18/2021 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | High | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/18/2021 |
COGT Cogent Biosciences | $7.84
+0.5% | 1/4/2021 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | N/A | View details for Lifesci Capital rating of Cogent Biosciences (NASDAQ:COGT) on 1/4/2021 |
CLDX Celldex Therapeutics | $25.14
-0.9% | 11/17/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Celldex Therapeutics (NASDAQ:CLDX) on 11/17/2020 |
TARS Tarsus Pharmaceuticals | $52.91
+1.8% | 11/10/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 11/10/2020 |
AVDL Avadel Pharmaceuticals | $10.31
+2.0% | 11/9/2020 | Reiterated by | Lifesci Capital | Analyst D. Sherman | Outperform | | Low | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/9/2020 |
ADVM Adverum Biotechnologies | $4.74
+0.9% | 11/5/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/5/2020 |
IFRX InflaRx | $2.24
+5.2% | 10/30/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Market Perform | | Low | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 10/30/2020 |
ALLK Allakos | $1.20
-7.0% | 10/22/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 10/22/2020 |
MEIP MEI Pharma | $2.50
+2.0% | 10/21/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of MEI Pharma (NASDAQ:MEIP) on 10/21/2020 |
RCKT Rocket Pharmaceuticals | $11.56
+1.9% | 10/16/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/16/2020 |
INBX Inhibrx | $14.60
+5.2% | 10/15/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 10/15/2020 |
IMVT Immunovant | $25.86
+0.8% | 10/6/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Immunovant (NASDAQ:IMVT) on 10/6/2020 |
VYNE VYNE Therapeutics | $2.50
+4.6% | 10/2/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 10/2/2020 |
ALXO ALX Oncology | $1.62
+9.5% | 9/30/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 9/30/2020 |
CRTX Cortexyme | $1.78
+1.1% | 9/24/2020 | Reiterated by | Lifesci Capital | Analyst D. Sherman | Outperform | | High | View details for Lifesci Capital rating of Cortexyme (NASDAQ:CRTX) on 9/24/2020 |
